Quality of life after gamma knife radiosurgery treatment in patients with a vestibular schwannoma: the patient’s perspective by Timmer, Ferdinand C. A. et al.
OTOLOGY
Quality of life after gamma knife radiosurgery treatment
in patients with a vestibular schwannoma: the patient’s
perspective
Ferdinand C. A. Timmer • Anniek E. P. van Haren • Jef J. S. Mulder • Patrick E. J. Hanssens •
Jacobus J. van Overbeeke • Cor W. R. J. Cremers • Kees Graamans
Received: 20 July 2009/Accepted: 16 October 2009/Published online: 6 November 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract This study evaluates the impact of gamma
knife radiosurgery (GKRS) on the quality of life (QOL) of
patients with a sporadic vestibular schwannoma (VS). This
study pertains to 108 VS patients who had GKRS in the
years 2003 through 2007. Two different QOL question-
naires were used: medical outcome study short form 36
(SF36) and Glasgow beneﬁt inventory (GBI). Radiosurgery
was performed using a Leksell 4C gamma knife. The
results of the QOL questionnaires in relation to prospec-
tively and retrospectively gathered data of the VS patients
treated by GKRS. Eventually, 97 patients could be inclu-
ded in the study. Their mean tumor size was 17 mm (range
6–39 mm); the mean maximum dose on the tumor was
19.9 Gy (range 16–25.5 Gy) and the mean marginal dose
on the tumor was 11.1 (range 9.3–12.5 Gy). SF36 scores
showed results comparable to those for a normal Dutch
population. GBI showed a marginal decline in QOL. No
correlation was found between QOL and gender, age,
tumor size, or radiation dose. Increased audiovestibular
symptoms after GKRS were correlated with a decreased
GBI score, and decreased symptoms were correlated with a
higher QOL post-GKRS. In this study shows that GKRS
for VS has little impact on the general QOL of the VS
patient. However, there is a wide range in individual QOL
results. Individual QOL was inﬂuenced by the audioves-
tibular symptoms. No predictive patient, tumor, or treat-
ment factors for QOL outcome after GKRS could be
determined. Comparison with microsurgery is difﬁcult
because of intra group variability.
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Introduction
A vestibular schwannoma (VS) is a benign tumor arising
from the vestibular part of the eighth cranial nerve.
Unilateral hearing loss, tinnitus, and unsteadiness are the
most common symptoms at the time of diagnosis [1]. These
symptoms inﬂuence the quality of life (QOL) of the VS
patient, as has been described in earlier papers [2, 3].
Tumor size is not found to be related to the amount and
severity of audiovestibular symptoms [3]. The growth
pattern of VSs is unpredictable. A large proportion of all
VSs show no growth in the ﬁrst years after diagnosis, and a
regression of tumor size has even been described in some
cases. When diagnosed, VS is rarely a life-threatening
condition, but large VSs need treatment to prevent brain-
stem compression. Due to the increased availability of
magnetic resonance imaging (MRI), VSs can now be
diagnosed at an earlier stage and their growth can be
monitored at regular intervals.
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aimed at controlling tumor growth and preserving cranial
nerve functions. Treatment options include conservative
management (wait and scan, W&S), microsurgery (MS),
and stereotactic radiation therapy. A well-known type of
stereotactic radiation therapy is gamma knife radiosurgery
(GKRS).
It has become a prominent treatment option for
VS\3 cm. Its tumor control rate is assumed to be com-
parable to that achieved by microsurgery, but the impact on
QOL appears to be less [4, 5]. Until the end of the twentieth
century, the minimal (12–20 Gy) and maximal (24–50 Gy)
tumor doses were relatively high and the planning was less
precise by current standards [6]. Whereas side effects and
complications related to GKRS seemed to be signiﬁcant in
the past, nowadays, the GKRS seems to be a treatment
option that does not pose any serious risks.
This study was carried out to evaluate the impact of
GKRS on the QOL of VS patients. The aim was to evaluate
audiovestibular symptoms and to correlate this data with
QOL parameters.
Patients and methods
Study population and study design
This study pertains to 108 patients who had GKRS in the
years 2003 through 2007. They were initially seen and
examined at the Department of Otorhinolaryngology, Head
and Neck Surgery of our tertiary referral center. Among the
reasons to proceed to GKRS were MRI-proven tumor
growth ([2 mm difference in maximal diameter of the
tumor in either direction on sequential MR images in the
axial plane) and the patient’s personal preference after
consultation.
Together with an information letter and questionnaire
about audiovestibular symptoms before and after treatment
with GKRS, two different QOL questionnaires were sent to
the patients after GKRS. Those unable to answer the
questionnaires were excluded from the study.
Quality of life questionnaires
Two questionnaires were used: the medical outcome study
short form 36 (SF36) and the Glasgow beneﬁt inventory
(GBI). The ﬁrst questionnaire, the SF36, was originally
constructed to survey health status in the Medical
Outcomes Study [7]. The short form 36 health survey
comprises 36 items, non-speciﬁc for disease, with two to
six response choices per item. The pre-coded responses
are recoded in percentages. Items falling into the same
category are averaged to create eight health concepts:
physical functioning, bodily pain, role limitations due to
physical health problems, role limitations due to personal
or emotional problems, emotional well-being, social
functioning, vitality, and general health perceptions. The
scores are presented with a minimum of zero and a
maximum of 100. A higher score means a higher health
state. Dutch norm scores are available for reference pur-
poses [8].
The second questionnaire is the Glasgow beneﬁt
inventory (GBI), a tool to measure patient beneﬁt that was
developed especially for otorhinolaryngological interven-
tions [9]. The questionnaire contains 18 post-intervention
items, eliciting responses based on a ﬁve-point Likert
scale. This scale ranges from a low health status,
expressed in a low score, to a high health status. In this
case, the items pertain to GKRS. Various scores can be
calculated from the item responses: the total score,
general subscale score, social support subscale score, and
physical health subscale score. The scores range from
-100 to 100, with a score of 0 indicating no health
change after an intervention and -100, a worsened health
state after treatment.
Tumor size
Tumor size was determined according to the consensus
reached in Tokyo on 7 November 2001 [10]. In the case
of extrameatal tumors, this involved measuring the
largest extrameatal diameter on axial MR images.
Intrameatal tumors were measured parallel to the internal
acoustic meatus (IAM). The intra- and extrameatal por-
tions of the tumor were clearly delineated by the con-
tinuation of the line of the petrous ridge depicted on
serial axial MR images. A tumor was classiﬁed as an
intrameatal lesion when there was no tumor extension
beyond that plane. All other tumors were recorded as
extrameatal lesions.
Complications and audiovestibular symptoms
There are several possible complications of GKRS: sen-
sorineural impairment, vestibular disorders, facial nerve
paresis (including lacrimal gland dysfunction), trigeminal
nerve dysfunction (disturbances of facial sensibility and
facial pain), recurrent tumor growth, headache, and com-
plications due to installing the stereotactic frame on the
head.
Since most of these complications could also be caused
by the VS itself, the symptoms before GKRS were com-
pared to those after GKRS. Patients were retrospectively
asked to indicate an increase, decrease, or no change of
symptoms. Furthermore, all patient charts were checked for
other complications or side effects of GKRS.
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radiation dose
A Leksell titanium stereotactic frame was installed on each
patient’s head after injecting a local anesthetic subcutane-
ously at the screw points in the skull. The patient was then
placed in a Philips T1.0 MRI scanner. Axial T1 1.0 mm
MR images were made before and after administering
gadolinium contrast. Then 3D TSE (Turbo Spin Echo)
0.7 mm images were constructed.
Using Leksell gamma-plan software V5.34, the tumor
was delineated on the corresponding images using the TSE
and T1-weighted gadolinium contrast enhanced images.
The tumor volume was then calculated using the 3D soft-
ware. A radiation plan was made by placing ‘isocenters’ or
‘shots’ in the tumor volume, guided by prescribed dose
(PD), marginal dose, and conformity. The cochlea was
pointed out on each axial MR image, and the maximal
radiation dose on the cochlea was calculated.
Stereotactic surgery was performed using a Leksell 4C
gamma knife. Treatment time depended on the radioac-
tivity of the sources and the number of shots. That number
was determined on the grounds of the tumor’s volume and
conﬁguration. Patients were discharged from the hospital
the same day.
Statistics
Statistical analysis was performed with SPSS (16.0). Sta-
tistical signiﬁcance was set at the 5% level. Summary
statistics (mean, SD, range) were expressed as a frequency
distribution. As the results of the questionnaires were
skewed, non-parametric tests were carried out to describe
the difference between groups. The Mann–Whitney U test
was used to compare two groups, the Kruskal–Wallis test
to compare more than two. Spearman’s rho was used for
continuous data. Even if the patients failed to complete the
entire questionnaire, the available data was used in the
calculations.
Results and analysis
Group characteristics
Of the initial 108 patients who underwent GKRS between
2003 and 2007, one patient had to be excluded since he was
unable to answer the questions due to dementia, presum-
ably not related to the VS or GKRS. Questionnaires were
returned by 97 of the remaining 107 patients (91%
response rate).
The responders had received the questionnaires after an
average period of 21 months (range 2–55 months)
following GKRS. The study group’s characteristics are
outlined in Table 1. The gamma knife settings and tumor
radiation doses are given in Table 2.
General quality of life after GKRS
The general QOL after GKRS of our study group was
assessed with the SF36 questionnaire. Here, the results are
compared to those for a normal Dutch population [8].
A t test showed that the RP and GH domains were sig-
niﬁcantly lower in our study group compared to the normal
population. The population characteristics and SF36 results
for the normal population and the study population are
given in Table 3.
Quality of life change after treatment
The GBI compared retrospectively the QOL of patients
before and after treatment with GKRS. Table 4 outlines the
results of the study population for this questionnaire. The
total scores and the three subscale scores are shown.
The mean total GBI score of -0.1 indicates a slight
negative change in the overall QOL after GKRS. The mean
social support score was above zero, which indicates better
social support after treatment. There was no signiﬁcant
difference in mean total GBI score between patients who
received the questionnaires within 12 months after GKRS
treatment and those who received the questionnaires later
(P = 0.409, Mann–Whitney U test).
No signiﬁcant difference was found between men and
woman for the mean total GBI score (P = 0.516, Mann–
Whitney U test). The GBI scores for patients younger than
40 years, patients from 40 to 60, and patients over 60 are
shown in Fig. 1. There seems to be a tendency toward
better QOL in older patients. However, signiﬁcance was
not reached in any of the domains.
The GBI scores calculated for patients with tumors
smaller than 10 mm, between 10 and 20 mm, and larger
Table 1 Descriptive statistics of the study group
Sex 52 Male/45 female
Mean age at VS diagnosis (years) 53 (range 23–81)
Mean age at GKRS (years) 56 (range 24–84)
Mean time between diagnosis and
GKRS (months)
27 (range 2–126)
Tumor side 58 Right (59.8%),
39 left (40.2%)
Tumor location 94 Extrameatal (96.9%),
3 intrameatal (3.1%)
Mean tumor size extrameatal (mm) 17 (range 6–39)
Mean tumor volume before GKRS
(mm
3)
2,721 (range 25–17,700)
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123than 20 mm did not show a signiﬁcant correlation between
the mean total score (P = 0.57 Kruskal–Wallis test) and
other scores. Figure 2 shows the different GBI scores for
patients classiﬁed by tumor size.
No correlation was found between the mean total GBI
score for maximal cochlea (P = 0.060, Spearman’s rho) or
maximal tumor radiation dose (P = 0.365, Spearman’s
rho). In addition, no signiﬁcance was reached for the mean
total GBI score and initial management; W&S or imme-
diate GKRS after diagnosis (P = 0.201, Mann–Whitney U
test).
The outcome of the audiovestibular symptom ques-
tionnaire is presented in Table 5. In retrospect, the patients
had their symptoms both before and after GKRS. Patients
who did not have a speciﬁc symptom before treatment but
did have it after treatment were placed in the ‘increased’
group.
Based on the audiovestibular questionnaire, the study
group was divided into three subgroups. Figure 3 shows the
GBI scores of the patients with increased, decreased, or
unaltered severity of the most common audiovestibular
symptoms in the population: tinnitus, hearing impairment,
and unsteadiness/vertigo. The mean general and total GBI
scores were signiﬁcantly higher when there was a total
decrease in the severity of the three symptoms. In case of
an increase in severity, the social support score was higher
and the physical score was lower, although this was not
signiﬁcant for both ﬁndings.
Compared with the maximal dosages at the tumor and
the cochlea, there is no positive relation with the groups
reporting decreased, unaltered, or increased symptoms.
A higher dose was not related to an increase in symptoms
as assessed with the audiovestibular symptom question-
naire. No secondary interventions because of recurrent
tumor growth have occurred so far.
Discussion
In our study population, we found that GKRS has a small
impact on the general QOL in VS patients. The QOL of VS
patients after GKRS was comparable to that of a normal
Table 2 Gamma knife settings and dosages at the tumor
Mean (Gy) Range (Gy) SD
Marginal dose 11.1 9.3–12.5 0.45
Tumor dose 90% 12.7 12–13.2 0.33
Maximal tumor dose 19.9 16–25.5 1.7
Maximal cochlea dose 10.4 5–16.1 2.69
The marginal dose is deﬁned as the minimal dose received by 100%
of the tumor. Tumor dose 90% is the amount of Gy minimally
received by 90% of the tumor
Table 3 SF36 study population and Dutch normal population
Study
population
n = 97
Normal
population [8]
n = 1,742
Unpaired
t test (P value)
Age receiving questionnaire
Mean (SD) 57.6 (13.3) 47.6 (18.0) <0.0001
Range 26–86 16–94
Sex
Male 54% 56%
Female 46% 44%
SF36
PF mean (SD) 82.5 (20.9) 83.0 (22.8) 0.83
RP mean (SD) 68 (40.6) 76.4 (36.3) 0.03
RE mean (SD) 80.7 (36.2) 82.3 (32.9) 0.64
VT mean (SD) 66.3 (22.4) 68.6 (19.3) 0.25
MH mean (SD) 80.1 (15.8) 76.8 (17.4) 0.06
SF mean (SD) 81.3 (22.1) 84.0 (22.4) 0.24
BP mean (SD) 78.4 (22.1) 74.9 (23.4) 0.15
GH mean (SD) 65.5 (20) 70.7 (20.7) 0.01
PF physical functioning, RP role limitations physical, RE role limi-
tations emotional, VT vitality, MH general mental health, SF social
functioning, BP bodily pain, GH general health, PH physical health,
EH emotional health, SD standard deviation
Signiﬁcant values are given in bold
Table 4 GBI total and subscale scores
Mean (n) SD Range
Study population (n = 97)
Total score -0.1 (71) 14.6 -33.3 to 52.8
General subscale score -1.4 (78) 19.3 -50 to 62.5
Social support subscale score ?6.7 (94) 18.8 -33.3 to 100
Physical health subscale score -4.9 (91) 12.5 -50 to 33.3
-10
-8
-6
-4
-2
0
2
4
6
8
10
Total score 
(p=0,237)
General subscale 
score (p=0,620)
Social support 
subscale score 
(p=0,207)
Physical health 
subscale score 
(p=0,712)
<40 yrs (n=10) 40-60 yrs (n=47) >60 yrs (n=40)
Fig. 1 GBI total and subscale scores for patients younger than
40 years, patients between 40 and 60 years, and patients older than
60 years. Signiﬁcance assessed by the Kruskal–Wallis test
870 Eur Arch Otorhinolaryngol (2010) 267:867–873
123Dutch population, as measured with the SF36 questionnaire.
Only the RP and GH domains were signiﬁcantly lower in
our study group compared to the normal population.
According to the mean total GBI score, the impact of
GKRS on the QOL was negligible. However, there is a
wide range in individual QOL results and a clear correla-
tion was found between the change in severity of audio-
vestibular complaints and the total GBI score. Our
measurements demonstrated that hearing symptoms were
unaltered in about 72%, increased in 22%, and decreased in
7% of the VS patients after GKRS.
Measuring QOL and comparing QOL study outcomes is
difﬁcult. The timing of the interview and the questions
asked may be decisive for the patient’s responses. Tumor
size often differs between study groups. The post-treatment
QOL outcome could be inﬂuenced by the doctor’s social
and surgical skills as well as by recurrent tumor growth
after GKRS or MS. In general, each selection bias or
comorbidity difference between different groups makes
comparison of these groups questionable [11]. Despite
these drawbacks, we think it is useful to take note of some
other studies, which used the same questionnaires, as they
put our ﬁndings in perspective.
SF36
The SF36 results measured in our study group are given in
Table 6 together with values for the normal Dutch popu-
lation. These results are placed alongside the SF36 results
found by other authors after MS, and after MS with VS
larger than 20 mm extrameatal diameter.
Our scores on the SF36 questionnaire after GKRS were
very similar to those for a normal Dutch population. This
suggests the presence of a small impact on the general
QOL for VS patients who underwent GKRS and therefore
also for VS patients in general.
In the other two studies after MS in VS patients, lower
scores were found in all domains compared to our post-
GKRS group [2, 12]. Conclusions based on comparisons
between these groups and our study group are questionable
because of differences in tumor size and follow-up time.
Myrseth et al. [13] recently published a prospective non-
randomized study. They also used the SF-36 to compare
QOL between GKRS and MS and did not ﬁnd any trend
toward a better or worse outcome for either treatment
group after 2 years of follow-up.
-10
-8
-6
-4
-2
0
2
4
6
8
10
Total score 
(p=0,570)
General subscale 
score (p=0,629)
Social support 
subscale score 
(p=0,901)
Physical health 
subscale score 
(p=0,725)
<10mm (n=14) 10mm-20mm (n=55) >20mm (n=28)
Fig. 2 GBI total and subscale scores for patients with tumors smaller
than 10, 10–20 mm, and larger than 20 mm. Signiﬁcance tested by
the Kruskal–Wallis test
Table 5 Audiovestibular
symptoms before and after
GKRS, and change in symptoms
after treatment
n = 97 Number of
patients
Before GKRS (%)
Number of
patients
After GKRS (%)
Decreased
symptom
(%)
Unaltered
(%)
Increased
symptom (%)
Tinnitus 78 (80) 84 (87) 6 (6) 67 (69) 24 (25)
Hearing impairment 89 (92) 93 (96) 6 (6) 70 (72) 21 (22)
Unsteadiness/vertigo 64 (66) 73 (75) 7 (7) 69 (71) 21 (22)
Facial function 3 (3.1) 10 (10) 0 89 (92) 8 (8)
Trigeminal function 17 (18) 28 (29) 4 (4) 78 (80) 15 (16)
Headache 47 (49) 55 (57) 6 (6) 76 (78) 15 (16)
-15
-10
-5
0
5
10
15
20
GBI total score 
(p=0,000)
General subscale 
score (p=0,000)
Social support 
subscale score 
(p=0,226)
Physical health 
subscale score 
(p=0,080)
Decreased symptoms Unaltered symptoms Increased symptoms
Fig. 3 Mean GBI scores for total decrease, increase, or no change in
tinnitus, hearing, and unsteadiness. **P\0.01 (Kruskal–Wallis test)
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The mean total GBI score we measured in our study group
was -0.1, which suggests a very small impact of GKRS on
the QOL. However, the standard deviation (14.6) and the
range (from -33.3 to 52.8) point at the presence of large
inter-individual variations.
We have tried to identify individual variables that could
explain these variations. In this search, we found some
indication of a better QOL after treatment in patients who
were diagnosed at an older age ([60 years), but this out-
come was not signiﬁcant.
Like previous results reported by many authors includ-
ing Myrseth et al., the three most common audiovestibular
symptoms before and after GKRS were tinnitus, hearing
loss, and unsteadiness [1]. The GBI results clearly show the
inﬂuence of these symptoms on the QOL.
In the literature, we found one study that assessed QOL
after MS by GBI [14]. To compare our results we divided
our study population into three separate groups: patients
whose QOL was better, worse or the same after GKRS
(Table 7).
Nikolopoulos et al. [15] recorded a decreased QOL in
54% of his patients after MS compared to our 37% after
Table 6 SF36 results for four study populations
Aaronson et al. [8]
Normal Dutch
population
Present study
n = 97
After GKRS
Tufarelli et al. [10]
n = 386
After MS
Nicoucar et al. [2]
n = 72
After MS VS[20 mm
Age receiving questionnaire
Mean (SD) 47.6 (18.0) 57.6 (13.3) 49 (12.1) 50.8 (–)
Range 16–94 26–86 – –
Sex
Male (%) 56 54 54 43
Female (%) 44 46 46 57
Mean tumor size 17 mm (6–39) Not mentioned [20 mm
Elapsed mean time since
treatment (Months)
21 49 91
SF36 Mean (SD) Mean (SD) Mean (SD) Mean
PF 83.0 (22.8) 82.5 (20.9) 77.8 (27.7) 72.5
RP 76.4 (36.3) 68 (40.6) 66.7 (40.6) 56.6
RE 82.3 (32.9) 80.7 (36.2) 67.7 (25.1) 67.1
VT 68.6 (19.3) 66.3 (22.4) 55.1 (23.9) 55.1
MH 76.8 (17.4) 80.1 (15.8) 61.7 (26.9) 66.8
SF 84.0 (22.4) 81.3 (22.1) 73.2 (25.4) 65.8
BP 74.9 (23.4) 78.4 (22.1) 67.9 (25.1) –
GH 70.7 (20.7) 65.5 (20) 60.6 (25.5) 68.2
PF physical functioning, RP role limitations physical, RE role limitations emotional, VT vitality, MH general mental health, SF social func-
tioning, BP bodily pain, GH general health, PH physical health, EH emotional health, SD standard deviation
Table 7 QOL after GKRS or
MS treatment, measured by GBI
Study population
After GKRS (n = 97)
Nikolopoulos et al. [13]
After MS (n = 53)
Age receiving questionnaire
Mean (SD) 57.6 (13.3) 49 (–)
Range 26–86 25–76
Mean tumor size (mm) 17 21.5
Elapsed time since treatment (years) Range 0.2–4.6 (mean 1.75) Range 1–3
QOL measured by GBI
Better (%) 39.4 17.4
Same (%) 23.9 28.8
Worse (%) 36.7 53.8
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found 17% compared to our 39%. Comparable results were
found by Myrseth et al. They retrospectively compared
their MS and GKRS results and concluded that post-
treatment QOL, as well as facial nerve functions, hearing,
and complication rate, were better after GKRS [4]. In their
latest study, these results could be reconﬁrmed [13]. This
retrospective study suggests that GKRS, when performed
with a relatively low radiation dose, has a low impact on
QOL in patients with VS.
To compare the QOL between patients treated by
GKRS and MS a prospective study, preferably random-
ized, with a patient group matched on tumor size and pre-
treatment symptoms is required. In the present study, the
audiovestibular symptoms were assessed retrospectively
and could therefore be biased. Moreover, these symptoms
were not objectively assessed. In that light, the results of
this study are not fully comparable to those found in the
literature.
Despite these shortcomings, this data offer further
insight into the patient’s opinion and perspective. This is
important since decision-making in VS cases increasingly
tends to be determined by the personal preference of the
patients involved.
Conclusion
This study showed that GKRS for VS has little impact on
the general QOL. However, the range of individual QOL
results is wide. Individual QOL is inﬂuenced by the
audiovestibular symptoms. No predictive patient, tumor, or
treatment factors for QOL outcome after GKRS can be
identiﬁed.
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